Figure 1. Preoperative chest X-ray showing a 2.5-cm round shadow in the left lung (a). CT revealed spicula and pleural indentation in S6 (b).
| Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc |
| Journal website http://www.journalmc.org |
Case Report
Volume 7, Number 11, November 2016, pages 484-487
Primary Lung Adenocarcinoma With Trophoblastic Differentiation and Usage of Gefitinib for Postoperative Recurrence: Report of a Case With a Review of the Literature
Figures
Table
| Year | Age | Gender | T | N | M | Stage | Operative procedure | Chemotherapy regimen | Combined cancer | Observation period (months) | Cause of death |
|---|---|---|---|---|---|---|---|---|---|---|---|
| F: female; M: male; NA: not available; PN: pneumonectomy; LB: lobectomy; WR: wedge resection; ND: no description; 5FU: 5-flourouracil; CTX: cyclophosphamide; PVP: cisplatin and etoposide; MA-CO: methotrexate, actinomycin D/oncovin, cyclophosphamide; PE: etoposide and cisplatin; MAC: methotrexate/leucovorin, actinomycin-D, and cyclophosphamide or chlorambucil; PACE: cisplatin, adriamycin and cytoxan; VPV: bleomycin by vinblastine; EMA: etoposide and cisplatin/etoposide, methotrexate, and actinomycin D; BOMP-EPI: bleomycin, vincristine, methotrexate, platinum/etoposide, platinum, ifosfamide; BEP: bleomycin, etoposide, cisplatin; CHAMOCA: cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, doxorubicin, melphalan and vincristine; MTX: methotrexate; UD: unknown details; NBC: nothing but choriocarcinoma; GCC: giant cell carcinoma; Sm: small cell carcinoma; Ad: adenocarcinoma; Sq: squamous cell carcinoma; La: large cell carcinoma; UDC: undifferentiated carcinoma; TR: treatment-related death; TD: tumor death. | |||||||||||
| 1952 | NA | F | 4 | NA | 1b | IV | PN | ND | ND | 0 | TR |
| 1954 | 29 | F | 3 | 2 | NA | NA | PN | ND | NBC | 3 | TD |
| 1977 | 45 | M | NA | NA | NA | NA | - | ND | GCC | 5 | TD |
| 1977 | 57 | M | NA | 3 | NA | NA | - | ND | GCC | 12 | TD |
| 1979 | 63 | M | NA | 3 | NA | NA | - | 5FU + CTX | Sm | 2 | TD |
| 1980 | 27 | M | NA | 0 | 0 | NA | LB | PVP | NBC | 4 | Alive |
| 1982 | 67 | M | 3 | NA | NA | NA | LB | ND | NBC | 36 | Alive |
| 1983 | 22 | F | 3 | NA | 1b | IV | - | ND | ND | 0 | TD |
| 1985 | 34 | F | 2a | 0 | 0 | IB | LB | UD | NBC | 6 | Alive |
| 1987 | 60 | F | 3 | 2 | 0 | IIIA | PN | ND | ND | 0 | TD |
| 1988 | 21 | F | NA | NA | 1b | IV | - | MA-CO | ND | NA | TD |
| 1989 | 51 | M | 3 | 2 | 1b | IV | - | ND | Non-Ad non-Sq | 0 | TD |
| 1989 | 37 | M | 3 | 2 | 0 | IIIA | PN | PE | La | 15 | TD |
| 1990 | 68 | M | 3 | NA | 0 | IIB-IIIB | LB | MAC, PE, PACE | La | 15 | Alive |
| 1992 | 55 | F | NA | NA | 0 | NA | LB | ND | La | NA | Alive |
| 1992 | 59 | F | NA | NA | 1b | IV | - | MAC | ND | 5 | TD |
| 1994 | 61 | M | 2b | 0 | 0 | IIA | PN | PVP or VPV | NBC | 1.5 | TR |
| 1994 | NA | M | 2b | 0 | 0 | NA | LB | PVP | NBC | 5 | TD |
| 1994 | 27 | F | 1b | NA | 0 | IA | LB | EMA, PE | Ad | 36 | Alive |
| 1995 | 69 | M | NA | NA | 1b | IV | - | UD | NBC | 1.5 | TD |
| 1996 | 54 | F | 3 | NA | 1b | IV | LB | BOMP/EPI | ND | 12 | Alive |
| 1996 | 29 | F | NA | 0 | NA | - | BEP, CHAMOCA, MTX | ND | 72 | Alive | |
| 1996 | 69 | M | 2a | 0 | 0 | IB | LB | BEP | NBC | 6 | Alive |
| 1997 | 69 | M | 3 | NA | 1b | IV | - | ND | La and UDC | 0 | ND |
| 2000 | 60 | M | 2 | 0 | 0 | IB or IIA | - | UD | NBC | 5 | TD |
| 2000 | 61 | M | 2 | 0 | 0 | IB or IIA | LB | ND | GCC | 5 | TD |
| 2001 | 61 | M | NA | NA | NA | NA | WR | BEP, EMA/CO | Ad | 6 | Alive |
| 2001 | 58 | M | NA | 2 | 0 | NA | LB | ND | La | 5 | TD |
| 2002 | 23 | M | NA | NA | 1a | IV | - | MAC | NBC | 0 | TD |
| 2003 | 37 | F | NA | NA | NA | NA | LB | BEP | NBC | 12 | Alive |
| 2006 | 77 | M | 2b | 3 | 1b | IV | - | ND | Ad and UDC | 0 | TD |